The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Where are we on anti-BCMA CAR T-cell therapies for MM?

During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to the Co-Chair of the hub, María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, Where are we on anti-BCMA CAR T-cell therapies for MM?

María-Victoria Mateos talks about idecabtagene vicleucel (ide-cel) and the results of the KarMMa trial, in addition to ciltacabtagene autoleucel (cilta-cel), in patients with relapsed/refractory MM. Maria


Share:

Your opinion matters

Test your knowledge! CAR-T products are more advanced than bsAbs/BiTEs in MM, and BCMA is the most popular target antigen
11 votes - 2 days left ...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox